Abstract: NU7441 (also known as 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one) is a highly potent and selective small-molecule inhibitor of the DNA-dependent protein kinase (DNA-PK). DNA-PK plays a pivotal role in the repair of DNA double-strand breaks (DSBs) through the non-homologous end joining (NHEJ) pathway. By competitively binding to the ATP-binding pocket of the DNA-PK catalytic subunit (DNA-PKcs), NU7441 effectively blocks NHEJ, thereby sensitizing cells to ionizing radiation and DNA-damaging chemotherapeutic agents. Developed through the structural optimization of earlier phosphatidylinositol 3-kinase (PI3K) inhibitors, NU7441 exhibits remarkable selectivity for DNA-PK over other PI3K-related kinases (PIKKs). Although its clinical translation has been limited by poor water solubility, NU7441 remains an extensively used and invaluable tool compound for functional studies of DNA-PK, DSB repair mechanisms, and the development of next-generation cancer therapies.
1. Introduction
DNA double-strand breaks (DSBs) are considered the most deleterious type of DNA damage, typically generated by ionizing radiation (IR) and various anticancer drugs [1]. In eukaryotic cells, DSBs are primarily repaired through two major pathways: homologous recombination (HR) and non-homologous end joining (NHEJ) [1]. NHEJ is the predominant repair mechanism, especially in the G1 and G0 phases of the cell cycle, and relies heavily on the DNA-dependent protein kinase (DNA-PK) [1].
DNA-PK is a molecular sensor for DSBs, composed of a large catalytic subunit (DNA-PKcs) and a Ku heterodimer (Ku70 and Ku80) that binds directly to DNA ends [1]. Because cells deficient in DNA-PKcs exhibit hypersensitivity to IR and DNA-damaging agents, the pharmacological inhibition of DNA-PK has emerged as a potent strategy for radiosensitization and chemosensitization in cancer therapy [1]. NU7441 was developed as a highly potent and selective DNA-PK inhibitor to exploit this vulnerability, serving as a critical agent for studying DNA-PK cellular functions and NHEJ inhibition [1].
2. Pharmacological Activity
NU7441 demonstrates exceptional pharmacological potency and selectivity against DNA-PK. In vitro assays reveal that NU7441 inhibits DNA-PK with an IC50 of 14 nM [1]. Its selectivity profile is highly favorable when compared to other kinases in the PIKK and PI3K families; it shows an IC50 of >100,000 nM for both Ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) kinases, 1700 nM for mTOR, and 5000 nM for PI3Kα [1].
In cellulo, NU7441 acts as a robust radiosensitizer and chemosensitizer. At a concentration of 0.5 µM, it significantly sensitizes cultured cells to ionizing radiation and the chemotherapeutic drug etoposide in a manner strictly dependent on the presence of DNA-PKcs [1]. Furthermore, NU7441 has shown efficacy in vivo; intraperitoneal (i.p.) administration of 10–25 mg/kg of NU7441 successfully potentiates tumor growth suppression when combined with radiation and chemotherapeutic drugs like etoposide in tumor xenograft models [1]. Interestingly, studies have also shown that the inhibition of DNA-PK by NU7441 can alleviate the toxicity of the PARP inhibitor olaparib in ATM-deficient cells [1].
3. Molecular Mechanism of Action
The molecular mechanism of NU7441 involves the direct and competitive inhibition of the DNA-PKcs ATP-binding site, which prevents the kinase from phosphorylating downstream targets essential for the NHEJ repair cascade [1]. Recent structural studies utilizing cryo-electron microscopy (cryo-EM) have elucidated the precise binding interactions between NU7441 and DNA-PKcs [1].
NU7441 binds deeply within the hydrophobic pockets of the DNA-PKcs active site. The chromen and morpholine groups of NU7441 are inserted into the deepest hydrophobic pocket formed by the amino acid residues Leu3751, Tyr3791, Ile3803, Leu3986, and Ile3940 [1]. Simultaneously, the dibenzothiophene group of the compound inserts into an adjacent hydrophobic pocket formed by Met3729, Pro3735, and Leu3751 [1]. These multiple, highly specific interactions stabilize the inhibitor within the enzyme, explaining the significantly higher affinity and selectivity of NU7441 for DNA-PKcs compared to earlier, less specific inhibitors like wortmannin [1].
4. Structure-Activity Relationship (SAR)
The development of NU7441 is a prime example of structure-guided evolution of kinase inhibitors. The compound was derived from earlier efforts to modify PI3K inhibitors, specifically LY294002, which possessed a morpholine ring structure essential for inhibitory activity but lacked selectivity (inhibiting DNA-PK with an IC50 of 6 µM) [1].
Screening of LY294002 derivatives first led to the discovery of NU7026, which improved DNA-PK IC50 to 230 nM [1]. Further structural optimization led to NU7441 (8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one). The retention of the morpholine and chromen-4-one structures, coupled with the addition of the bulky dibenzothiophene group, allowed the molecule to exploit the unique, deep hydrophobic pockets of DNA-PKcs [1]. This specific structural arrangement is responsible for driving the IC50 down to 14 nM and achieving orders-of-magnitude selectivity over ATM, ATR, and PI3Ks [1].
5. Current Limitations
Despite its high potency and selectivity, the primary limitation of NU7441 is its poor water solubility, which restricts its pharmacokinetic profile and clinical applicability [1]. Because of these physicochemical limitations, NU7441 has largely remained a preclinical tool compound rather than progressing into human clinical trials [1]. To overcome this barrier, researchers have had to synthesize derivatives with improved aqueous solubility. For example, KU-0060648 was developed directly by modifying NU7441 to increase water solubility, though this modification resulted in a dual inhibitor that also targets PI3Ks at lower concentrations [1]. Another derivative, NU5455, was later developed to maintain high selectivity while allowing for oral administration without adverse effects in normal tissues [1].
6. Future Perspectives
While NU7441 itself may not advance to the clinic, it has laid the critical foundational groundwork for the development of next-generation, clinically viable DNA-PK inhibitors such as M3814 (peposertib) and AZD7648, which are currently in Phase 1 and 2 clinical trials [1]. Furthermore, NU7441 remains one of the most frequently used small molecules in functional and mechanistic studies of DNA-PK and the NHEJ pathway [1]. By reliably inhibiting NHEJ, NU7441 continues to be an indispensable pharmacological tool for researchers investigating DNA damage responses, exploring synthetic lethality (such as in ATM-deficient backgrounds), and developing novel combinatorial strategies involving radiotherapy and chemotherapy [1].
